Corcept Therapeutics reports Q3 EPS 41c, consensus 28c

Reports Q3 revenue $182.5M, consensus $172.0M. “In the third quarter, we added more Korlym(R) prescribers and more patients received Korlym treatment than ever before,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. “Physicians are increasingly aware of hypercortisolism’s true prevalence and of the poor health outcomes of patients who go untreated. Screening is becoming more common and the number of patients receiving appropriate care continues to increase. For patients and physicians who choose Korlym, our extensive system of support services is critical to optimizing the benefit of our medication.”